We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ACTAIR Initiation Treatment 100IR and 300IR; ACTAIR Continuation Treatment 300IR (Stallergenes Australia Pty Ltd)
Product name
ACTAIR Initiation Treatment 100IR and 300IR; ACTAIR Continuation Treatment 300IR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
203 (255 working days)
Active ingredients
American house dust mite; European house dust mite
Registration type
EOI
Indication
ACTAIR Initiation Treatment 100IR and 300IR; ACTAIR Continuation Treatment 300IR (sublingual tablet) is now also approved for treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.